Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company's successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

Arthur Levin, a founding member of Avidity, serves as Distinguished Scientist and Strategic Leader at Avidity Biosciences and is a member of the Board of Directors. He previously held the position of Chief Scientific Officer at Avidity. Dr. Levin is a key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. Prior to joining Avidity, Dr. Levin was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharma.

Dr. Levin has played key roles in the development of numerous oligonucleotides including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has a combined three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin has published more than 100 scientific articles and several of the most cited reviews in the field. He is on the scientific advisory boards of multiple institutions. Art received a doctorate in toxicology from the University of Rochester, and a bachelor’s degree in biology from Muhlenberg College.

Dr. Steve Hughes, Chief Medical Officer, joined Avidity Biosciences in February 2022. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams. He has contributed to over 50 clinical trials for more than 25 drugs across all stages of drug development and in multiple therapeutic areas including cardiovascular, neurology and several rare diseases with successful license approvals for several rare disease drugs. Dr. Hughes’s previous positions include the Chief Medical Officer at Arcturus and Organovo, Chief Clinical Development Officer at Ionis Pharmaceuticals and clinical leadership positions at Biogen, CSL Behring and Sanofi. Dr. Hughes is board certified in pharmaceutical medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.

W. Michael Flanagan, Chief Scientific and Technical Officer, joined Avidity Biosciences in January 2021. Dr. Flanagan has extensive experience developing multiple therapeutic modalities, including RNA therapeutics, antibody drug conjugates, and bispecific antibodies. Prior to joining Avidity, Dr. Flanagan served as Senior Director and Project Team Leader, Oncology and Immunology for Genentech, Inc., where he advanced programs through late-stage research to end of Phase 2 development. Prior to Genentech, he served in roles of increasing responsibility in the biology groups at Sunesis Pharmaceuticals, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. where he was Senior Director of RNA Sciences. Dr. Flanagan received a B.S. in Genetics from the University of California at Davis, a Ph.D. in Biological Sciences from the University of California at Irvine and was an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute, Stanford University.

Michael MacLean, Chief Financial and Chief Business Officer, joined Avidity Biosciences Inc in 2020. Mike brings more than 30 years of strategic financial leadership within life sciences and other industries to Avidity, with deep experience in funding biotechnology companies to advance novel therapies in the rare and orphan disease space. In addition, his past roles included working with growing global commercial teams to support multiple product launches.  Prior to Avidity, Mike served as Chief Financial Officer of Akcea Therapeutics, Inc., another company focused on RNA therapies, where he led the buildout of Akcea's financial and commercial infrastructure, and also served as Chief Financial Officer of PureTech Health, plc. In addition, he held the position of Chief Accounting Officer of Biogen Inc. where he led the company's worldwide finance operations. Mike currently serves as member of the board of directors at Verve Therapeutics.

Teresa McCarthy, Chief Human Resources Officer, joined Avidity Biosciences in August 2020. Ms. McCarthy is responsible for developing and executing human resource strategies in support of Avidity's overall business plan and strategic direction. She brings to Avidity decades of experience as an organizational development and human resources consultant in the life science industry. Ms. McCarthy has worked with biotech and healthcare companies at all stages of development via her consulting firm, McCarthy Consultants Inc., and her long-term partnership with The Leadership Edge, Inc. Prior to consulting, Ms. McCarthy held leadership positions at Edwards Lifesciences, Baxter Cardiovascular Group, and IVAC Corporation and received an M.A. degree in Organizational Communication with an emphasis in International Business from San Diego State University.

Eric Mosbrooker has over 20 years of experience in global commercial operations, with demonstrated leadership and experience in global pricing, marketing, distribution, product launches, and compliance. In addition to his commercial experience, Mr. Mosbrooker has expertise in gene therapy, rare metabolic diseases, additional orphan conditions and oncology. Most recently, Mr. Mosbrooker served as the Chief Operations Officer for Cognoa, leading the commercial, program management, product, and business operations functions. Before Cognoa, he was the Chief Commercial Officer at Audentes Therapeutics overseeing the gene therapy business unit and the Senior Vice President of the Global Orphan Business Unit at Horizon Pharmaceuticals. He holds a B.S. in Industrial Engineering from the University of Wisconsin – Madison.

John B. Moriarty, Jr., J.D. has served as our Chief Legal Officer and Corporate Secretary since August 2024. Prior to joining the Company, Mr. Moriarty served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Mirati Therapeutics, Inc. from May 2023 to January 2024, when it was acquired by Bristol-Myers Squibb Co. Previously, from September 2020 to April 2023, Mr. Moriarty served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Olema Pharmaceuticals, Inc., and from March 2018 to July 2020, he served as Executive Vice President, General Counsel and Secretary of Portola Pharmaceuticals, Inc., which was acquired by Alexion Pharmaceuticals, Inc. in July 2020. From September 2014 to February 2018, Mr. Moriarty served as Executive Vice President and General Counsel of Alexion Pharmaceuticals, Inc., and from December 2012 to September 2014, he served as Senior Vice President and General Counsel of Alexion. Prior to joining Alexion, he served as General Counsel and Senior Vice President at Elan Corporation plc, an Irish public limited company traded on the New York and Irish Stock Exchanges, and also served as a member of Elan’s Executive Management team from March 2010 to December 2012. Prior to assuming the role of General Counsel and Senior Vice President, Mr. Moriarty served as Senior Vice President, Law, Litigation and Commercial Operations at Elan from December 2008 to March 2010. From 2002 to 2008, Mr. Moriarty held various positions with Amgen Inc., including Executive Director and Associate General Counsel, Global Commercial Operations and Senior Counsel, Complex Litigation, Products Liability and Government Investigations. From 1999 through 2002 Mr. Moriarty was in private practice with a national law firm.  From 1994 to 1999, Mr. Moriarty served in various capacities in private practice focused on healthcare and as a healthcare fraud prosecutor in the U.S. Attorney’s Office and the Virginia Attorney General’s Office. Mr. Moriarty received a B.A. from the University of Virginia and a J.D. cum laude from the University of Georgia School of Law.

Kathleen Gallagher joined Avidity Biosciences in April 2021 and serves as Chief Program Officer. She previously held the roles of Senior Vice President and Global Program Head, Myotonic Dystrophy Type 1 (DM1) and Senior Vice President of Corporate Communications and Investor Relations. Ms. Gallagher brings more than 20 years of experience in the biopharmaceutical industry leading communications and investor relations in preclinical to commercial stage companies. Prior to joining Avidity, she was Vice President, Investor Relations and Corporate Communications at Akcea Therapeutics (acquired by Ionis Pharmaceuticals), where her communications strategy and relationship building expertise were essential through the development and commercial launches of rare disease therapies Tegsedi® and Waylivra®. Previously, she held roles of increasing responsibility during her 13-year tenure at Merrimack Pharmaceuticals, where she provided leadership and direction through multiple financing rounds including an IPO and through the launch of the pancreatic cancer therapy ONIVYDE®. Ms. Gallagher earned her B.S. degree in English from Boston University.